modelTriamcinolone
Extends from Pharmacolibrary.Drugs.ATC.S.S01BA05.
Information
| name: | Triamcinolone | |
| ATC code: | S01BA05 | route: | intravitreal |
| compartments: | 1 | |
| dosage: | 4 | mg |
| volume of distribution: | 1.47 | L |
| clearance: | 0.049 | ml/h |
| other parameters in model implementation | ||
Triamcinolone is a synthetic corticosteroid with potent anti-inflammatory, immunosuppressive, and anti-allergic properties. It is primarily used for the treatment of various ocular inflammatory conditions such as uveitis, allergic conjunctivitis, and post-surgical ocular inflammation. The drug, particularly triamcinolone acetonide, is approved and in clinical use today, especially as intraocular or periocular steroid injections.
Pharmacokinetics
Pharmacokinetic parameters after single intravitreal administration of triamcinolone acetonide in adult patients with macular edema.
References
Beer, PM, et al., & Miller, M (2003). Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110(4) 681–686. DOI:10.1016/S0161-6420(02)01969-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12689886
Dutra Medeiros, M, et al., & Nucci, P (2014). Effectiveness of the Dexamethasone Intravitreal Implant for Treatment of Patients with Diabetic Macular Oedema. European endocrinology 10(2) 111–116. DOI:10.17925/EE.2014.10.02.111 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29872474
Audren, F, et al., & Bergmann, JF (2004). Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Investigative ophthalmology & visual science 45(10) 3435–3441. DOI:10.1167/iovs.03-1110 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15452046
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)